San Diego-based diagnostics startup Mane Cancer Diagnostics has formed its management team (see related story, this issue). It will be headed by Evan Levine, who will serve as president, CEO, and a company director. Ian Wisenberg will join him as a director and as chief financial officer.
The company has also hired, as consultants, Joan Robbins as chief scientific officer and Mark Erwin as chief business officer.
Levine is currently a managing partner of investment firm Mark Capital. Before that he was CEO of Adventrx Pharmaceuticals.
Wisenberg is a founder and managing partner of BioGlobal Consulting Group and BioGlobal Ventures as well as co-founder and managing director of ChinaBio Capital Partners.
Robbins is currently the senior director of cancer biology at Tocohen and was previously senior vice president and chief scientific officer at Adventrx as well as a researcher at the National Cancer Institute, the Garvin Institute for Medical Research, and the University of California, San Diego. Erwin is senior director of reimbursement and government affairs at Prometheus Laboratories and was previously senior vice president of commercialization at Adventrx.
Roche said this week that it has appointed Daniel O'Day, current COO of Roche Diagnostics, to be COO of Roche Pharma, taking over for Pascal Soriot, who has left the firm to become CEO of AstraZeneca. Roland Diggelmann will succeed O'Day as COO of Roche Diagnostics.
Diggelmann, who currently is head of the Asia-Pacific region within Roche Diagnostics, also has been appointed to be a new member of the executive committee by the board of directors. Diggelmann joined Roche in 2008 and formerly worked in sales and marketing in Europe and the Asia-Pacific region with Sulzer Medica/Centerpulse and Zimmer.
O’Day has held various positions at Roche since he started with Roche Pharmaceuticals in 1987, including serving as head of molecular diagnostics.